Altogen Labs
Altogen Labs is a leading contract research organization (CRO) based in Austin, Texas, specializing in preclinical research services for pharmaceutical, biotechnology, and academic institutions worldwide. The company focuses on oncology, gene silencing, xenograft models, and advanced biotechnology services, including the development of stable cell lines, RNA interference (RNAi), and in vivo imaging. With extensive experience in cancer research, xenograft models, and gene modulation, Altogen Labs aims to accelerate drug development and personalized medicine through innovative and GLP-compliant solutions.
Industries
Nr. of Employees
small (1-50)
Altogen Labs
Austin, Texas, United States, North America
Products
Xenograft Models
Altogen Labs offers over 50 xenograft cancer animal models for biodistribution, PK/PD, and imaging studies, providing detailed experiment procedures, health reports, and experimental data.
Preclinical Studies
Altogen Labs conducts safety in vivo toxicology studies, efficacy studies, drug discovery, drug development, and other R&D studies including safety toxicology, biodistribution, ADME, and imaging studies.
CRO Services
Altogen Labs provides pharma/biotechnology research services, including in vivo and in vitro services such as IC50 assays, stable cell line development, gene function and expression analysis, RNAi and CRISPR lab services, and liposome encapsulation.
Stable Cell Line Development
Altogen Labs offers stable cell line development within 28 days, including gene function and expression analysis, RNAi and CRISPR lab services, and liposome encapsulation.
RNAi Services
Altogen Labs provides complete RNAi services from oligonucleotide design to tissue-targeted delivery, including in vitro siRNA testing, encapsulation, and tissue-targeted siRNA delivery into animals.
T-47D Xenograft Model
The T-47D xenograft model is used for breast cancer research, particularly for evaluating the efficacy of potential drug candidates.
Xenograft Models
Altogen Labs offers over 50 xenograft cancer animal models for biodistribution, PK/PD, and imaging studies, providing detailed experiment procedures, health reports, and experimental data.
Preclinical Studies
Altogen Labs conducts safety in vivo toxicology studies, efficacy studies, drug discovery, drug development, and other R&D studies including safety toxicology, biodistribution, ADME, and imaging studies.
CRO Services
Altogen Labs provides pharma/biotechnology research services, including in vivo and in vitro services such as IC50 assays, stable cell line development, gene function and expression analysis, RNAi and CRISPR lab services, and liposome encapsulation.
Stable Cell Line Development
Altogen Labs offers stable cell line development within 28 days, including gene function and expression analysis, RNAi and CRISPR lab services, and liposome encapsulation.
RNAi Services
Altogen Labs provides complete RNAi services from oligonucleotide design to tissue-targeted delivery, including in vitro siRNA testing, encapsulation, and tissue-targeted siRNA delivery into animals.
T-47D Xenograft Model
The T-47D xenograft model is used for breast cancer research, particularly for evaluating the efficacy of potential drug candidates.
Services
Xenograft animal studies and model selection (CDX, PDX, syngeneic, orthotopic, humanized)
Design and execution of efficacy and translational oncology studies using a broad repository of validated xenograft and PDX models with IACUC-regulated animal care and GLP-aligned data capture. Services include model selection consulting, tumorigenicity and metastasis assessments, hematology and histopathology endpoints, dosing/schedule/route optimization, and support for biomarker screening and PK/PD integration. Repository counts reported include ~89 CDX, ~29 PDX and >40 syngeneic models.
In vivo toxicology and safety testing (OECD/GLP-aligned)
Acute, sub-chronic and chronic toxicology studies, toxicokinetic analyses and associated endpoints with data packages intended for regulatory review.
RNAi and oligonucleotide delivery services (in vitro and in vivo)
End-to-end RNAi services including oligonucleotide design, synthesis, chemical modification, liposomal or nanoparticle encapsulation (microfluidics options), in vitro validation, tissue-targeted in vivo delivery and quantitative knockdown analysis.
Stable cell line generation and inducible knockdown/overexpression lines
Development of stable mammalian cell lines for protein expression or gene knockdown, including inducible systems, cloning and expedited production timelines.
Cell banking and cryopreservation services (GLP-aligned)
Cryopreservation, master/working cell bank generation and controlled storage to preserve cell viability and identity with GLP-compliant procedures.
Microorganism identification, sequencing and genomic characterization
16S rRNA-based identification and whole-genome sequencing with bioinformatic annotation to support R&D, environmental and patent-related workflows.
Xenograft animal studies and model selection (CDX, PDX, syngeneic, orthotopic, humanized)
Design and execution of efficacy and translational oncology studies using a broad repository of validated xenograft and PDX models with IACUC-regulated animal care and GLP-aligned data capture. Services include model selection consulting, tumorigenicity and metastasis assessments, hematology and histopathology endpoints, dosing/schedule/route optimization, and support for biomarker screening and PK/PD integration. Repository counts reported include ~89 CDX, ~29 PDX and >40 syngeneic models.
In vivo toxicology and safety testing (OECD/GLP-aligned)
Acute, sub-chronic and chronic toxicology studies, toxicokinetic analyses and associated endpoints with data packages intended for regulatory review.
RNAi and oligonucleotide delivery services (in vitro and in vivo)
End-to-end RNAi services including oligonucleotide design, synthesis, chemical modification, liposomal or nanoparticle encapsulation (microfluidics options), in vitro validation, tissue-targeted in vivo delivery and quantitative knockdown analysis.
Stable cell line generation and inducible knockdown/overexpression lines
Development of stable mammalian cell lines for protein expression or gene knockdown, including inducible systems, cloning and expedited production timelines.
Cell banking and cryopreservation services (GLP-aligned)
Cryopreservation, master/working cell bank generation and controlled storage to preserve cell viability and identity with GLP-compliant procedures.
Microorganism identification, sequencing and genomic characterization
16S rRNA-based identification and whole-genome sequencing with bioinformatic annotation to support R&D, environmental and patent-related workflows.
Expertise Areas
- Preclinical oncology models and PDX workflows
- In vivo pharmacology, toxicology and PK/PD
- RNAi therapeutics development and delivery
- Stable cell line generation and inducible expression systems
Key Technologies
- Microfluidics-based liposome production
- Lipid- and polymer-based nanoparticle delivery
- PEGylation and biodegradable lipid/polymer chemistries
- High-throughput 96-cell-line screening panels